1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Hong, M.
Cady, S.D.
Mishanina, T.V.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C10 H17 N
151.249
(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]decan-1-amine
Amantadine
non-polymer
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
UK
J.Mol.Biol.
JMOBAK
0070
0022-2836
385
1127
1141
10.1016/j.jmb.2008.11.022
19061899
Structure of amantadine-bound M2 transmembrane peptide of influenza A in lipid bilayers from magic-angle-spinning solid-state NMR: the role of Ser31 in amantadine binding.
2009
US
Proc.Natl.Acad.Sci.USA
PNASA6
0040
0027-8424
105
1483
1488
10.1073/pnas.0711500105
18230730
Amantadine-induced conformational and dynamical changes of the influenza M2 transmembrane proton channel.
2008
US
J.Phys.Chem.B
JPCBFK
1278
1089-5647
111
10825
10832
10.1021/jp073823k
17705425
Side-chain conformation of the M2 transmembrane peptide proton channel of influenza a virus from 19F solid-state NMR.
2007
US
J.Am.Chem.Soc.
JACSAT
0004
0002-7863
128
7242
7251
10.1021/ja0603406
16734478
Determination of the oligomeric number and intermolecular distances of membrane protein assemblies by anisotropic 1H-driven spin diffusion NMR spectroscopy.
2006
10.2210/pdb2kad/pdb
pdb_00002kad
2688.215
Transmembrane peptide of Matrix protein 2
Transmembrane peptide of influenza A M2 protein: UNP residues 22-46
4
syn
polymer
151.249
(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]decan-1-amine
1
syn
non-polymer
Proton channel protein M2
no
no
SSDPLVVAASIIGILHLIAWILDRL
SSDPLVVAASIIGILHLIAWILDRL
A,B,C,D
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
13C and 15N chemical shifts of DLPC-bound M2(22-46) measured by solid-state NMR.
database_2
pdbx_nmr_software
pdbx_nmr_spectrometer
pdbx_struct_assembly
pdbx_struct_oper_list
struct_ref_seq_dif
struct_site
repository
Initial release
Version format compliance
Data collection
Database references
Derived calculations
1
0
2008-11-18
1
1
2011-07-13
1
2
2021-10-20
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_nmr_software.name
_pdbx_nmr_spectrometer.model
_struct_ref_seq_dif.details
_struct_site.pdbx_auth_asym_id
_struct_site.pdbx_auth_comp_id
_struct_site.pdbx_auth_seq_id
BMRB
Y
RCSB
2008-11-04
REL
REL
308
(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]decan-1-amine
Solid phase peptide synthesis
sample
structures with the least restraint violations
1
1
2D 13C-13C DQF_COSY
2D 15N-13C HETCOR
2D DARR
2D INADEQUATE
4-6
mg/mL
Selective U-13C, 15N labeled
15-25
mg/mL
10
mM
0.1
mM
1
mM
20-25
mg/mL
7.5
ambient
243
K
TALOS
torsion angle dynamics
1
fewest violations
4-6 mg/mL Selective U-13C, 15N labeled M2 Transmembrane Peptide, 15-25 mg/mL DLPC, 10 mM sodium phosphate, 0.1 mM sodium azide, 1 mM EDTA, 20-25 mL H2O, Solid-State NMR: Hydrated DLPC gel, approx. 50% H2O by weight. DLPC:M2TMP:Amantadine 15:1:8
Solid-State NMR: Hydrated DLPC gel, approx. 50% H2O by weight. DLPC:M2TMP:Amantadine 15:1:8
Bruker Biospin
collection
TopSpin
1.3
Accelrys Software Inc.
structure solution
Insight II
2005
Accelrys Software Inc.
refinement
Insight II
2005
600
Bruker
AVANCE
Bruker AVANCE
400
Bruker
DRX
Bruker DRX
308
1
2
308
308
1
A
SER
22
n
1
SER
22
A
SER
23
n
2
SER
23
A
ASP
24
n
3
ASP
24
A
PRO
25
n
4
PRO
25
A
LEU
26
n
5
LEU
26
A
VAL
27
n
6
VAL
27
A
VAL
28
n
7
VAL
28
A
ALA
29
n
8
ALA
29
A
ALA
30
n
9
ALA
30
A
SER
31
n
10
SER
31
A
ILE
32
n
11
ILE
32
A
ILE
33
n
12
ILE
33
A
GLY
34
n
13
GLY
34
A
ILE
35
n
14
ILE
35
A
LEU
36
n
15
LEU
36
A
HIS
37
n
16
HIS
37
A
LEU
38
n
17
LEU
38
A
ILE
39
n
18
ILE
39
A
ALA
40
n
19
ALA
40
A
TRP
41
n
20
TRP
41
A
ILE
42
n
21
ILE
42
A
LEU
43
n
22
LEU
43
A
ASP
44
n
23
ASP
44
A
ARG
45
n
24
ARG
45
A
LEU
46
n
25
LEU
46
A
SER
22
n
1
SER
22
B
SER
23
n
2
SER
23
B
ASP
24
n
3
ASP
24
B
PRO
25
n
4
PRO
25
B
LEU
26
n
5
LEU
26
B
VAL
27
n
6
VAL
27
B
VAL
28
n
7
VAL
28
B
ALA
29
n
8
ALA
29
B
ALA
30
n
9
ALA
30
B
SER
31
n
10
SER
31
B
ILE
32
n
11
ILE
32
B
ILE
33
n
12
ILE
33
B
GLY
34
n
13
GLY
34
B
ILE
35
n
14
ILE
35
B
LEU
36
n
15
LEU
36
B
HIS
37
n
16
HIS
37
B
LEU
38
n
17
LEU
38
B
ILE
39
n
18
ILE
39
B
ALA
40
n
19
ALA
40
B
TRP
41
n
20
TRP
41
B
ILE
42
n
21
ILE
42
B
LEU
43
n
22
LEU
43
B
ASP
44
n
23
ASP
44
B
ARG
45
n
24
ARG
45
B
LEU
46
n
25
LEU
46
B
SER
22
n
1
SER
22
C
SER
23
n
2
SER
23
C
ASP
24
n
3
ASP
24
C
PRO
25
n
4
PRO
25
C
LEU
26
n
5
LEU
26
C
VAL
27
n
6
VAL
27
C
VAL
28
n
7
VAL
28
C
ALA
29
n
8
ALA
29
C
ALA
30
n
9
ALA
30
C
SER
31
n
10
SER
31
C
ILE
32
n
11
ILE
32
C
ILE
33
n
12
ILE
33
C
GLY
34
n
13
GLY
34
C
ILE
35
n
14
ILE
35
C
LEU
36
n
15
LEU
36
C
HIS
37
n
16
HIS
37
C
LEU
38
n
17
LEU
38
C
ILE
39
n
18
ILE
39
C
ALA
40
n
19
ALA
40
C
TRP
41
n
20
TRP
41
C
ILE
42
n
21
ILE
42
C
LEU
43
n
22
LEU
43
C
ASP
44
n
23
ASP
44
C
ARG
45
n
24
ARG
45
C
LEU
46
n
25
LEU
46
C
SER
22
n
1
SER
22
D
SER
23
n
2
SER
23
D
ASP
24
n
3
ASP
24
D
PRO
25
n
4
PRO
25
D
LEU
26
n
5
LEU
26
D
VAL
27
n
6
VAL
27
D
VAL
28
n
7
VAL
28
D
ALA
29
n
8
ALA
29
D
ALA
30
n
9
ALA
30
D
SER
31
n
10
SER
31
D
ILE
32
n
11
ILE
32
D
ILE
33
n
12
ILE
33
D
GLY
34
n
13
GLY
34
D
ILE
35
n
14
ILE
35
D
LEU
36
n
15
LEU
36
D
HIS
37
n
16
HIS
37
D
LEU
38
n
17
LEU
38
D
ILE
39
n
18
ILE
39
D
ALA
40
n
19
ALA
40
D
TRP
41
n
20
TRP
41
D
ILE
42
n
21
ILE
42
D
LEU
43
n
22
LEU
43
D
ASP
44
n
23
ASP
44
D
ARG
45
n
24
ARG
45
D
LEU
46
n
25
LEU
46
D
author_defined_assembly
4
tetrameric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
1
B
D
HB1
HG13
ALA
ILE
30
35
0.89
1
A
D
HG13
HB1
ILE
ALA
35
30
0.93
1
B
C
HG13
HB1
ILE
ALA
35
30
0.95
1
A
C
HB1
HG13
ALA
ILE
30
35
0.99
1
A
C
O
HD13
ALA
ILE
30
35
1.42
1
A
D
HD13
O
ILE
ALA
35
30
1.43
1
B
D
O
HD12
ALA
ILE
30
35
1.47
1
B
C
HD13
O
ILE
ALA
35
30
1.49
1
A
D
HD12
O
ILE
ALA
35
30
1.49
1
B
C
HD12
O
ILE
ALA
35
30
1.50
1
B
D
O
HD13
ALA
ILE
30
35
1.50
1
A
C
O
HD12
ALA
ILE
30
35
1.52
1
A
C
HE2
CE2
HIS
TRP
37
41
1.55
1
B
C
CE2
HE2
TRP
HIS
41
37
1.55
1
A
D
HD21
ND1
LEU
HIS
38
37
1.60
1
A
D
CD1
O
ILE
ALA
35
30
1.72
1
A
C
O
CD1
ALA
ILE
30
35
1.73
1
B
D
O
CD1
ALA
ILE
30
35
1.73
1
B
C
CD1
O
ILE
ALA
35
30
1.74
1
B
C
CD2
NE2
TRP
HIS
41
37
1.95
1
A
C
NE2
CD2
HIS
TRP
37
41
1.96
1
B
D
NE2
CD2
HIS
TRP
37
41
2.04
1
A
D
CD2
NE2
TRP
HIS
41
37
2.05
1
A
C
CD2
CZ3
HIS
TRP
37
41
2.11
1
B
C
CZ3
CD2
TRP
HIS
41
37
2.15
1
A
D
CZ3
CD2
TRP
HIS
41
37
2.19
1
6.76
0.90
118.30
125.06
A
A
A
CB
CG
OD1
ASP
ASP
ASP
24
24
24
N
1
7.61
0.90
118.30
125.91
A
A
A
CB
CG
OD1
ASP
ASP
ASP
44
44
44
N
1
-6.60
0.90
118.30
111.70
A
A
A
CB
CG
OD2
ASP
ASP
ASP
44
44
44
N
1
-3.16
0.50
120.30
117.14
A
A
A
NE
CZ
NH2
ARG
ARG
ARG
45
45
45
N
1
6.68
0.90
118.30
124.98
B
B
B
CB
CG
OD1
ASP
ASP
ASP
24
24
24
N
1
7.59
0.90
118.30
125.89
B
B
B
CB
CG
OD1
ASP
ASP
ASP
44
44
44
N
1
-6.61
0.90
118.30
111.69
B
B
B
CB
CG
OD2
ASP
ASP
ASP
44
44
44
N
1
-3.20
0.50
120.30
117.10
B
B
B
NE
CZ
NH2
ARG
ARG
ARG
45
45
45
N
1
6.74
0.90
118.30
125.04
C
C
C
CB
CG
OD1
ASP
ASP
ASP
24
24
24
N
1
7.55
0.90
118.30
125.85
C
C
C
CB
CG
OD1
ASP
ASP
ASP
44
44
44
N
1
-6.53
0.90
118.30
111.77
C
C
C
CB
CG
OD2
ASP
ASP
ASP
44
44
44
N
1
-3.31
0.50
120.30
116.99
C
C
C
NE
CZ
NH2
ARG
ARG
ARG
45
45
45
N
1
6.69
0.90
118.30
124.99
D
D
D
CB
CG
OD1
ASP
ASP
ASP
24
24
24
N
1
7.53
0.90
118.30
125.83
D
D
D
CB
CG
OD1
ASP
ASP
ASP
44
44
44
N
1
-6.56
0.90
118.30
111.74
D
D
D
CB
CG
OD2
ASP
ASP
ASP
44
44
44
N
1
-3.23
0.50
120.30
117.07
D
D
D
NE
CZ
NH2
ARG
ARG
ARG
45
45
45
N
1
A
A
C
OXT
LEU
LEU
46
46
-0.139
0.019
1.229
1.090
N
1
B
B
C
OXT
LEU
LEU
46
46
-0.139
0.019
1.229
1.090
N
1
C
C
C
OXT
LEU
LEU
46
46
-0.137
0.019
1.229
1.092
N
1
D
D
C
OXT
LEU
LEU
46
46
-0.140
0.019
1.229
1.089
N
13C and 15N chemical shifts of DLPC-bound M2(22-46) measured by solid-state NMR.
Magic-Angle-Spinning Solid-State NMR Structure of Influenza A M2 Transmembrane Domain
1
N
N
1
N
N
1
N
N
1
N
N
2
N
N
A
SER
22
A
SER
1
HELX_P
A
LEU
46
A
LEU
25
1
1
25
B
SER
22
B
SER
1
HELX_P
B
LEU
46
B
LEU
25
1
2
25
C
SER
22
C
SER
1
HELX_P
C
LEU
46
C
LEU
25
1
3
25
D
SER
22
D
SER
1
HELX_P
D
LEU
46
D
LEU
25
1
4
25
MEMBRANE PROTEIN
transmembrane helix, proton channel, lipid bilayers, influenza A, Alternative splicing, Hydrogen ion transport, Ion transport, Ionic channel, Lipoprotein, Palmitate, Phosphoprotein, Signal-anchor, Transport, Virion, MEMBRANE PROTEIN
M2_I97A1
UNP
1
22
O70632
SSDPLVVAASIIGILHLILWILDRL
22
46
2KAD
22
46
O70632
A
1
1
25
22
46
2KAD
22
46
O70632
B
1
1
25
22
46
2KAD
22
46
O70632
C
1
1
25
22
46
2KAD
22
46
O70632
D
1
1
25
1
LEU
engineered mutation
ALA
40
2KAD
A
O70632
UNP
40
19
2
LEU
engineered mutation
ALA
40
2KAD
B
O70632
UNP
40
19
3
LEU
engineered mutation
ALA
40
2KAD
C
O70632
UNP
40
19
4
LEU
engineered mutation
ALA
40
2KAD
D
O70632
UNP
40
19
BINDING SITE FOR RESIDUE 308 A 1
A
308
1
Software
5
A
ALA
30
A
ALA
9
5
1_555
A
SER
31
A
SER
10
5
1_555
A
GLY
34
A
GLY
13
5
1_555
B
ALA
30
B
ALA
9
5
1_555
B
SER
31
B
SER
10
5
1_555